US009084728B2

(12) **United States Patent**
Goessl et al.

(10) **Patent No.: US 9,084,728 B2**
(45) **Date of Patent: Jul. 21, 2015**

(54) **PROCESS FOR MAKING DRY AND STABLE HEMOSTATIC COMPOSITIONS**

(75) Inventors: **Andreas Goessl**, Vienna (AT); **Atsushi Edward Osawa**, San Francisco, CA (US); **Cary J. Reich**, Los Gatos, CA (US)

(73) Assignees: **Baxter International Inc.**, Deerfield, IL (US); **Baxter Healthcare S.A.**, Glattpark (Opfikon) (CH)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 6 days.

(21) Appl. No.: **13/151,048**

(22) Filed: **Jun. 1, 2011**

(65) **Prior Publication Data**

US 2012/0121532 A1 May 17, 2012

Related U.S. Application Data

(60) Provisional application No. 61/350,266, filed on Jun. 1, 2010.

(51) **Int. Cl.**

A61K 38/57	(2006.01)
A61K 9/16	(2006.01)
A61K 9/00	(2006.01)
A61K 9/19	(2006.01)
A61K 38/48	(2006.01)
A61L 24/04	(2006.01)
A61L 24/10	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 9/1658*** (2013.01); ***A61K 9/0014*** (2013.01); ***A61K 9/19*** (2013.01); ***A61K 38/4833*** (2013.01); ***A61L 24/043*** (2013.01); ***A61L 24/10*** (2013.01); ***A61L 24/106*** (2013.01); *A61L 2400/04* (2013.01); *Y10T 428/13* (2015.01)

(58) **Field of Classification Search**

USPC 424/78.35, 78.31, 78.38, 94.64; 428/34.1

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,507,244	A	5/1950	Correll
2,558,395	A	6/1951	Studer
4,013,078	A	3/1977	Field
4,124,705	A	11/1978	Rothman et al.
4,164,559	A	8/1979	Miyata et al.
4,179,400	A	12/1979	Tsao et al.
4,265,233	A	5/1981	Sugitachi et al.
4,291,013	A	9/1981	Wahlig et al.
4,292,972	A	10/1981	Pawelchak et al.
4,298,598	A	11/1981	Schwarz et al.
4,300,494	A	11/1981	Graiff et al.
4,347,234	A	8/1982	Wahlig et al.
4,362,567	A	12/1982	Schwarz et al.
4,377,572	A	3/1983	Schwarz et al.
4,424,208	A	1/1984	Wallace et al.
4,453,939	A	6/1984	Zimmerman et al.
4,482,386	A	11/1984	Wittwer et al.
4,515,637	A	5/1985	Cioca
4,536,387	A	8/1985	Sakamoto et al.
4,540,410	A	9/1985	Wood et al.
4,543,332	A	9/1985	Jao et al.
4,554,156	A	11/1985	Fischer
4,600,574	A	7/1986	Lindner et al.
4,640,834	A	2/1987	Eibl et al.
4,655,211	A	4/1987	Sakamoto et al.
4,746,514	A	5/1988	Warne
4,749,689	A	6/1988	Miyata et al.
4,752,466	A	6/1988	Saferstein et al.
4,803,075	A	2/1989	Wallace et al.
4,818,517	A	4/1989	Kwee et al.
4,832,686	A	5/1989	Anderson
4,837,285	A	6/1989	Berg et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CN	1270240	A	10/2000
EP	0132983	A	2/1985

(Continued)

OTHER PUBLICATIONS

Ansell et al., "Gelfoam and Autologous Clot Embolization: Effect on Coagulation", *Invest. Radiol.* (1978) 13:115-120.

Barrow, D.L., et al.; "The Use of Greater Omentum Vascularized Free Flaps for Neurosurgical Disorders Requiring Reconstruction"; J. Neurosurg.; vol. 60; pp. 305-311 (Feb. 1984).

Barton et al., "Fibrin Glue as a Biologic Vascular Patch—A Comparative Study" (abstract posted at http://www.ncbi.nlm.nih.gov/ on Jan. 3, 2001 from) *J. Surg. Res.* (1986) 40(5): 510-513.

Baxter product brochure for TissuFleece E, TissuCone E and TissuFoil E (2003).

Baxter Product Catalogue; Collagen; 4 pages (2006).

Boyers et al., "Reduction of Postoperative Pelvic Adhesions in the Rabbit with Gore-Tex Surguical Membrane" *Fert. Ster.* (1988) 49(6):1066-1070.

(Continued)

Primary Examiner — Michael G Hartley
Assistant Examiner — Robert Cabral
(74) *Attorney, Agent, or Firm* — Kilpatrick Townsend & Stockton LLP

(57) **ABSTRACT**

Described is a process for making a dry and stable hemostatic composition, said process comprising

a) providing a first component comprising a dry preparation of a coagulation inducing agent,

b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis,

c) providing said first component and said second component in a combined form in a final container,

c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container,

c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container,

d) finishing the final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.

21 Claims, No Drawings